Newlink genetics corp (NLNK)
CashFlow / Quarterly
Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11
Cash Flows From Operating Activities
Net loss

-8,271

-14,548

-10,134

-10,036

-10,569

-7,403

-17,313

-18,310

-13,686

-20,626

-16,726

-20,913

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-23,720

-

-15,906

-14,091

11,190

-

-5,598

-9,163

-9,236

-

-8,123

-7,077

-7,934

-

-5,851

-6,309

-4,842

-5,810

-3,986

-4,394

-3,898

Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation

746

2,259

1,773

1,944

3,500

4,623

4,177

4,820

3,570

4,370

4,593

5,975

3,588

3,875

4,528

4,716

3,546

3,273

5,930

3,191

1,712

3,297

1,499

2,105

1,231

1,107

1,061

966

661

629

1,169

736

1,135

431

611

368

Depreciation and amortization

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

304

283

297

261

256

256

210

213

212

215

201

197

175

-

-

-

-

Depreciation and amortization

1,213

33

191

208

244

264

303

334

343

357

347

360

548

332

609

595

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

172

174

174

Forgiveness of debt

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

397

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Impairment of fixed assets

-

-

-

-

-

-

-

-

-

-

-

-

-18

0

3,976

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on sale of fixed assets

20

-35

-10

5

-118

-18

9

25

-24

11

-109

-4

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-18

-40

0

20

0

0

0

0

Amortization of right-of-use assets

-

-

-

-16

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

In-process research and development expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

0

0

0

0

0

Forgiveness of debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

0

0

0

0

0

Forgiveness of notes receivable from related parties

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

0

0

0

0

0

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

-266

-704

-433

-1,088

616

-323

-373

-146

3,525

-2,215

-4,068

3,063

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other current assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2,122

-

-9,576

119

2,892

7,981

-93

-233

-94

368

-130

-122

-250

762

-419

38

117

-408

529

11

418

State research and development credit receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

257

-466

-18

80

88

-228

122

-192

85

88

382

-85

-45

118

-230

60

80

Interest due on notes receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-8

Other receivables

15

282

153

-154

-241

-117

-9,535

-330

-494

-588

1,613

-14,881

9,532

11,815

-3,634

1,426

-9,589

1,982

1,949

7,330

996

2,559

-90

-1,077

105

410

356

261

170

845

-291

-724

489

-8

0

-65

Accounts payable and accrued expenses

-1,597

4,346

78

-848

-1,280

-5,887

-3,955

-1,907

-3,969

-144

-1,605

-9,751

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,501

-

2,227

-5,636

1,629

4,409

3,473

145

-129

841

-102

210

-106

53

133

-53

-1,042

934

-57

-103

-137

Income taxes receivable, net

87

348

-12

-2

7,059

-7,038

-21

17

-382

6,173

0

-312

-778

-938

-2,463

-2,655

935

-4,398

11,671

1,414

-1,260

-7,507

0

-125

130

0

0

0

-

-

-

-

-

-

-

-

Unearned revenue

0

0

0

0

0

0

0

-56

-56

-55

-56

-168

538

-201

-193

-212

-210

-237

-2,756

-9,549

14,051

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Deferred rent

0

0

0

0

14

27

26

25

24

23

22

22

829

24

24

31

11

21

20

21

21

20

21

21

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-8,031

-6,833

-7,830

-7,513

-1,317

-15,010

-6,936

-14,676

-17,211

-7,156

-10,905

-13,009

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3,439

-3,555

-4,336

Accrued expenses and deferred rent

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,031

781

335

-

355

525

-35

166

300

228

-418

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-19,507

-

-7,024

-6,390

-2,321

130,677

-8,506

-7,036

-6,067

-8,062

-6,279

-4,854

-6,623

-6,661

-3,361

-4,809

-5,640

-

-

-

-

Cash Flows From Investing Activities
Purchase of certificates of deposit

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

1,992

0

0

2,490

0

0

0

Maturity of certificates of deposit

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-4,618

-5,233

0

0

0

0

-249

-498

-747

-1,245

0

-1,743

0

0

-250

-1,750

-269

Maturity of certificates of deposit

-

-

-

-

-

-

-

-

-

-

-

-

0

0

997

1,183

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Notes receivable from related parties

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

0

0

0

0

0

Purchase of equipment

-

-

-

-

-

-

-

-

0

-14

22

35

177

85

1,703

281

545

1,277

1,440

733

356

1,047

204

93

106

1,006

212

62

186

23

405

709

187

40

6

48

Proceeds on sale of equipment

62

6

4

5

6

10

25

83

69

13

150

22

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

50

0

0

0

0

Cash paid for OncoRx

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

0

0

0

0

0

Net cash provided by investing activities

62

6

4

5

6

10

18

83

69

27

128

-13

-177

-85

-706

902

491

-291

2,133

3,885

3,887

-17,434

-204

-93

-355

-757

286

685

1,059

-2,015

1,338

-659

-2,677

210

1,744

221

Cash Flows From Financing Activities
Cash received from noncontrolling interest investment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

0

0

0

0

0

Issuance of common stock, net of offering costs

-30

0

30

0

-269

33

130

106

53,831

20,132

390

63

-1,686

1,111

532

43

-3,696

1,127

1,161

14,942

-1,810

135

436

28,811

16,934

7

381

49,035

-764

213

574

135

37,556

18

0

0

Repurchase of common stock

2

1

1

32

8

4

2

261

29

15

8

237

69

0

13

0

220

0

72

269

0

40

0

182

0

0

0

0

0

0

0

4

-13

0

0

0

Principal payments on notes payable

-

17

15

14

-

34

35

69

-

63

68

54

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repayments of notes receivable for common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-13

Proceeds from preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

0

0

0

5,000

0

Proceeds from notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

456

0

0

0

0

0

0

Principal payments on notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

72

-

48

57

39

72

38

39

38

38

37

37

37

36

24

24

23

23

21

25

23

Payments under capital lease obligations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

9

-

5

9

9

10

9

15

32

32

39

21

30

34

31

30

31

Net cash (used in) provided by financing activities

-9

-18

14

-46

-12

-5

93

-224

55,148

20,054

314

-228

405

1,052

455

-29

6,340

1,079

1,041

14,625

4,770

149

388

28,582

17,744

-39

329

48,966

295

606

529

78

37,499

-34

4,945

-41

Net decrease in cash and cash equivalents

-

-

-

-7,554

-

-

-

-14,817

-

12,925

-10,463

-13,250

-16,786

-12,251

-16,459

-18,634

-1,521

-6,236

-3,216

16,189

139,334

-25,791

-6,852

22,422

9,327

-7,075

-4,239

43,028

-5,307

-4,770

-2,942

-6,221

33,203

-3,263

3,134

-4,156

Supplemental disclosure of cash flows information:
Cash paid for interest

-

-

-

1

-

-

-

3

-

3

4

4

4

6

5

7

68

27

4

6

8

5

9

4

9

7

10

8

11

7

10

10

11

16

4

11

Cash paid for taxes, net

-

0

12

2

-

-5

22

-17

-

-6,263

0

2

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash paid for taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1

1,021

6

4,553

0

255

26,300

143

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Purchased leasehold improvements and equipment in accounts payable

-

-

-

-

-

-

-

-

-

-

-4

18

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Equipment acquired by capital lease

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

231

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Forgiveness of debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

397

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion on redeemable preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

0

1

2

5

0

Purchased leasehold improvements and equipment in accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

53

409

-89

79

10

-145

74

62

9

48

-17

-151

173

457

24

0

0

Common stock issued to shareholders of OncoRx as part of acquisition

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

0

0

0

0

0

Issuance of common stock dividend to Series AA preferred shareholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

0

1

0

0

0

Assets acquired under capital lease

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

181

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

5

75

0

Reduction of IPO offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

158

0

0

0

-

-

-

-